DaVita Inc. is a healthcare provider focused on kidney care, delivering dialysis services, integrated care, and disease management for patients with chronic kidney disease and end-stage renal disease. The company operates three primary business segments: U.S. dialysis, which provides outpatient dialysis, administrative, and laboratory services; U.S. integrated kidney care, which offers comprehensive care management and value-based care arrangements; and international operations, which provide dialysis and administrative services outside the United States. DaVita serves patients across the kidney health journey, from slowing disease progression to supporting transplantation, utilizing care models in home settings, dialysis centers, hospitals, and skilled nursing facilities. The company maintains partnerships with nephrologists, payors, and transplant programs, and participates in value-based care models such as the Comprehensive Kidney Care Contracting model. DaVita also operates ancillary services including DaVita Venture Group, DaVita Clinical Research, and DaVita Physician Solutions. The company sold its DaVita Medical Group business in 2019.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Care Facilities Homepage davita.com
Sector Healthcare IR page investors.davita.com
Tags
dialysis, kidney care, chronic kidney disease, end-stage renal disease, value-based care, clinical research, patient care management, nephrology, transplant support, home dialysis, DaVita Integrated Kidney Care, DaVita Venture Group, DaVita Clinical Research, DaVita Physician Solutions, DaVita Medical Group, myDaVita, Kidney Smart, Expanded HD
Press page investors.davita.com/feed-types/press-releases

Metrics

Valuation  
Market cap $ 11.439B
Market cap (USD) $ 11.439B
P/E 13.36
PEG 1.38
P/BV -19.35
P/S 0.81
P/OCF 6.12
P/FCF 8.84
Dividend yield —
Turnover / mcap —
Returns  
ROE -114.7%
ROI 7.8%
ROIC 16.6%
Profit margin 5.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 9.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 13.643B 12.816B 12.14B 11.61B 11.619B 11.04B 10.918B 10.71B — — — — — — — — — 5.66B 5.264B 4.881B 2.974B 2.299B 2.016B 1.855B 1.651B 1.486B
Net profit 746.803M 936.342M 691.535M 560.4M 978.45M 773.642M 810.981M 159.394M 663.618M 879.874M 269.732M 723.114M 633.446M 536.017M 478.001M 405.683M 422.684M 374.16M 381.778M 289.691M 228.643M 222.254M 175.791M 157.329M 137.315M —
Free cash flow 1.311B 1.467B 1.491B 961.141M 1.289B 1.304B 1.306B 784.502M 1.002B 1.134B 849.202M 818.077M 1.156B 550.702M 779.89M 566.081M 392.105M 237.969M 260.824M 256.863M 324.189M 291.617M 193.376M 239.283M 221.5M 266.56M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 113.61 149.55 104.76 74.67 113.76 117.4 75.03 51.46 72.25 64.2 69.71 75.74 63.37 110.53 75.8 69.49 58.74 49.58 57 56.1 — — — — — —
Price performance 12m -0.24 0.43 0.4 -0.34 -0.03 0.56 0.46 -0.29 0.13 -0.08 -0.08 0.2 -0.43 0.46 0.09 0.18 0.18 -0.13 0.02 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.92B 1.71B 1.86B 1.8B 1.82B 1.96B 2.13B 1.99B 2.15B 2.41B
↳ YoY growth +11.2% -10.6% +8.4% -3.4% +1.6% +7.3% +8.9% -6.8% +8.1% +12.5%
↳ 5y CAGR +9.9% +3.8% +4.6% +3.3% +1.1% +0.4% +4.5% +1.3% +3.6% +5.8%
Borrowings, current (USD) 165M 178M 1.93B 131M 169M 179M 231M 123M 271M 109M
Borrowings, non-current (USD) 8.95B 9.16B 8.17B 7.98B 7.92B 8.73B 8.69B 8.27B 9.18B 10.2B
Lease liabilities (USD) — — 0.00 3.07B 3.11B 3.07B 2.9B 2.72B 2.62B 2.6B
Cash and deposits (USD) 913M 508M 323M 1.1B 325M 462M 244M 380M 795M 676M
Intangible assets (USD) 1.53B 114M 119M 136M 167M 178M 183M 203M 197M 222M
Right-of-use assets (USD) — — 0.00 2.83B 2.86B 2.82B 2.67B 2.5B 2.39B 2.4B
Net debt (borrowings + leases - cash) (USD) 8.2B 8.83B 9.78B 10.1B 10.9B 11.5B 11.6B 10.7B 11.3B 12.2B
Cash flow detail
Operating cash flow (USD) 1.96B 1.91B 1.77B 2.07B 1.98B 1.93B 1.56B 2.06B 2.02B 1.89B
Purchases of property, plant and equipment (USD) -829M -905M -987M -767M -675M -641M -603M -568M -555M -576M
Change in receivables (cash effect) (USD) -152M -156M -81.2M -80M -21.1M -138M -148M 172M -29.8M -211M
Change in inventories (cash effect) (USD) 22.9M -18.6M 73.5M 10.2M -12.3M 5.72M -757,000 -32.1M 17.9M -20M
Change in payables (cash effect) (USD) 11.9M 26.9M -36M -84.5M 37.2M -30.3M 87.5M 26.9M 1.7M 128M
Dividends paid (cash effect) (USD) — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share buybacks (cash effect) (USD) -1.1B -803M -1.16B -2.38B -1.46B -1.54B -802M -272M -1.39B -1.31B
Interest paid (cash effect) (USD) -407M -425M -489M -473M -326M -279M -351M -388M -423M -515M
Income taxes paid (cash effect) (USD) -339M -387M -92.5M -158M -155M -210M -344M -268M -388M -177M
Share-based compensation (USD) 38.3M 35.1M 73.1M 67.9M 91.5M 102M 95.4M 112M 103M 140M
Operating cash flow before change in receivables (USD) 2.12B 2.06B 1.85B 2.15B 2B 2.07B 1.71B 1.89B 2.05B 2.1B
Free cash flow (OCF - PPE - intangibles) (USD) 1.13B 1B 785M 1.31B 1.3B 1.29B 961M 1.49B 1.47B 1.31B
Income detail
Total comprehensive income (USD) 1B 933M 293M 1.01B 976M 1.14B 852M 974M 992M 1.27B
Comprehensive income to owners (USD) 850M 766M 120M 798M 755M 905M 630M 709M 678M 935M
Provision for credit losses (USD) 11.7M -7.03M -7.3M — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.6% 0.4% 0.4% — — — — — — —
Reported Feb 24, 2017 Feb 23, 2018 Feb 12, 2021 Feb 21, 2020 Feb 12, 2021 Feb 11, 2022 Feb 22, 2023 Feb 14, 2024 Feb 13, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

  • Mail

  • X

  • Linkedin

  • Facebook

  • Print

At the American Society of Nephrology (ASN) Kidney Week this year, DaVita Clinical Research’s study “Exploring Patient Perspectives on Reasons for Missing Dialysis Treatments” shed vital light on this challenge.  

The research reveals that 63% of missed treatments stem from acute, same-day circumstances — most often health symptoms rather than logistical or scheduling conflicts.  

In this Q&A, Dr. Francesca Tentori, vice president of outcomes research and patient empowerment for DaVita and an author on the study, shares what these patient-reported insights mean, including how the right approaches to patient education, care coordination and communication can help turn vulnerable moments into proactive interventions.  

Explore the study results here.  

What gap in kidney care prompted this study? 

Dr. Tentori: We have long recognized that missed dialysis treatments correlate with higher morbidity, hospitalizations and other negative health outcomes.  

Our team sought to examine the patients’ perspective and experience by surveying a large cohort of patients who had skipped at least one dialysis session over the course of a month. This approach allowed us to uncover the real, lived reasons behind missed sessions, understand how patients perceive the risks of skipping treatment and evaluate how teams can respond to help patients get back on track.  

What did the study learn about patients’ experiences of missing treatments?  

Dr. Tentori: Among 224 responders nearly two-thirds (63%) of missed treatments were unplanned, and acute health concerns were the single largest driver, accounting for nearly half (48%) of missed treatments.  

While nearly half of the patients surveyed worried that missing treatment would harm their health, their concerns didn’t correlate with a higher likelihood of rescheduling their treatment. They were most concerned about the symptoms they would experience. Only about one-third of patients proactively intended to make up for their missed treatment.  

That disconnect is where the care team can make an incredible difference. Our findings clearly indicated that proactive outreach from the dialysis care team resulted in a higher likelihood of rescheduling the treatment.  

How can this help care teams shift conversations to promote proactive care?  

Dr. Tentori: It’s critical we continue to educate patients on how missed treatments affect their health. What this study reinforces, though, is why we’re focused on building workflows centered on proactive, empathetic engagement with patients.  

It’s about not only sharing with patients why missing treatments can be harmful but also making sure they know how to set up a replacement treatment. It’s about not only recording in their medical record when someone doesn’t show up but also initiating outreach to find out why and set up a rescheduled treatment. A call to someone when they don’t show up serves as a clinical check-in as well as an opportunity to work with the patient to reassure them and help them find an opening to come in and get the treatment they need.  

Ultimately, our mission is to ensure that every patient has access to the support systems and flexibility they need in their everyday, lived experiences.

Related Articles

The Sound of a Second Chance: DaVita Patients Celebrate Receiving Their Kidney Transplant

[The Sound of a Second Chance: DaVita Patients Celebrate Receiving Their Kidney Transplant](https://newsroom.davita.com/sound-of-second-chance-kidney-transplant-celebrations/ "

		Read full article: The Sound of a Second Chance: DaVita Patients Celebrate Receiving Their Kidney Transplant			")

The journey to receiving a kidney transplant can be a complex and deeply emotional experience. To navigate the intricate path that includes education, care coordination and personal support, patients often rely on their multidisciplinary care teams as they work to reach this life-changing milestone. DaVita teammates — from facility administrators and social workers to patient […]

Read more

How do GLP-1s have an impact on people starting PD?

[How do GLP-1s have an impact on people starting PD?](https://newsroom.davita.com/glp-1-peritoneal-dialysis-outcomes/ "

		Read full article: How do GLP-1s have an impact on people starting PD?			")

A large-scale, longitudinal study from DaVita Clinical Research presented at ASN Kidney Week bridges a vital clinical trial gap, examining GLP-1 use and clinical outcomes in home dialysis. Key Takeaways Closing a critical evidence gap: While major clinical trials have previously excluded individuals requiring dialysis, this study of 5,900 DaVita patients provides real-world data supporting […]

Read more

A Turning Point: A Kidney Diagnosis Leads to a Path Toward Healing

[A Turning Point: A Kidney Diagnosis Leads to a Path Toward Healing](https://newsroom.davita.com/peritoneal-dialysis-on-navajo-nation-patient-story/ "

		Read full article: A Turning Point: A Kidney Diagnosis Leads to a Path Toward Healing			")

“Learning I had kidney disease was a big turning point,” Nobert Mike remembers. Nobert shares that he had a hard life growing up: “I lost a lot of good people, lost a lot of good things in my life.” He, like many other people he knows living on Navajo Nation, struggled with alcohol addiction. Eventually, […]

Read more

Jump to Top

DENVER, Nov. 3, 2026 /PRNewswire/ — DaVita Inc. (NYSE: DVA) today announced that its Chief Financial Officer, Joel Ackerman, and its Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at the following upcoming investor conferences:

UBS Global Healthcare Conference 2026

Date: Monday, November 9, 2026

Fireside Chat Presentation: 1:15 pm EST

To view the live webcast, visit the UBS conference page  and create a free registration.

Wolfe Research Healthcare Conference 2026

Date: Tuesday, November 10, 2026

Fireside Chat Presentation: 8:40 am EST

To view the live webcast, visit the Wolfe conference page  and create a free registration.

About DaVita Inc.

DaVita (NYSE: DVA) is a healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey — from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of September 30, 2026, we provided dialysis services to a total of approximately 298,100 patients at 3,269 outpatient dialysis centers, of which 2,671 centers were located in the United States and 598 centers were located in 14 countries outside of the United States. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About .

DaVita Inc. 3rd Quarter 2026 Results Bull 3 Bear 0 Results

DENVER, Oct. 29, 2026 /PRNewswire/ — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026.

Financial and operating highlights for the quarter ended September 30, 2026:

  • Consolidated revenues were $3.578 billion.
  • Operating income was $499 million and adjusted operating income was $561 million.
  • Diluted earnings per share was $3.40 and adjusted diluted earnings per share was $3.82.
  • Operating cash flow was $519 million and free cash flow was $276 million.
  • Repurchased 0.6 million shares of the Company’s common stock at an average price paid of $186.21 per share.
Three months ended Nine months ended September 30,
September 30, 2026 June 30, 2026 2026 2025
Net income attributable to DaVita Inc.: (dollars in millions, except per share data)
Net income $             223 $             265 $              686 $             513
Diluted per share $            3.40 $            4.02 $           10.27 $            6.62
Adjusted net income(1) $             250 $             265 $              713 $             576
Adjusted diluted per share(1) $            3.82 $            4.02 $           10.67 $            7.44
_______________________
(1) For definitions of non-GAAP financial measures, see the note titled “Note on Non-GAAP Financial Measures” and related reconciliations beginning on page 14.
Three months ended Nine months ended September 30,
September 30, 2026 June 30, 2026 2026 2025
Amount Margin Amount Margin Amount Margin Amount Margin
Operating income (dollars in millions)
Operating income $   499 14.0 % $   579 16.3 % $ 1,560 14.8 % $ 1,483 14.8 %
Adjusted operating income(1) $   561 15.7 % $   579 16.3 % $ 1,622 15.4 % $ 1,508 15.0 %
_______________________
(1) For definitions of non-GAAP financial measures, see the note titled “Note on Non-GAAP Financial Measures” and related reconciliations beginning on page 14.

U.S. dialysis metrics:

Volume: Total U.S. dialysis treatments for the third quarter of 2026 were 7,329,644, or an average of 92,780 treatments per day, representing a per day increase of 0.1% compared to the second quarter of 2026. Normalized non-acquired treatment growth in the third quarter of 2026 compared to the third quarter of 2025 was 0.4%.

Three months ended Quarterchange Nine months ended Year to date change
September 30, 2026 June 30, 2026 September 30, 2026 September 30, 2025
(dollars in millions, except per treatment data)
Revenue per treatment $    415.25 $      415.87 $      (0.62) $     416.22 $    405.15 $        11.07
Patient care costs per treatment $    280.22 $      277.40 $       2.82 $     279.24 $    271.23 $          8.01
General and administrative $         316 $           331 $         (15) $          967 $         917 $             50

Primary drivers of the changes in the table above were as follows:

Revenue: The quarter change was primarily driven by normal fluctuations, partially offset by an increase in average reimbursement rates and improvements in payor mix. The year to date change was driven by typical annual rate increases and other normal fluctuations, partially offset by unfavorable changes in payor mix.

Patient care costs: The quarter change was primarily due to increased medical supplies expenses. The year to date change was primarily driven by increased compensation expenses, medical supplies expense, insurance costs and health benefits expenses.

General and administrative: The quarter change was primarily due to decreased professional fees. The year to date change was primarily driven by increases in IT-related costs and compensation expenses, partially offset by costs related to the cybersecurity incident experienced by the Company in 2025.

Certain items impacting the quarter:

Goodwill and other asset impairment charges. During the quarter ended September 30, 2026, we recognized non-cash goodwill and other asset impairment charges related to our business in China. The effect was a $62 million impairment charge within operating income, offset by a $1 million tax benefit and $34 million noncontrolling interest credit, resulting in a $27 million net income impact attributable to DaVita Inc.

Share repurchases. During the three months ended September 30, 2026, we repurchased 0.6 million shares for $111 million, at an average price paid of $186.21 per share.

Subsequent to September 30, 2026 through October 27, 2026, the Company has repurchased 0.5 million shares of our common stock for $87 million at an average price paid of $180.57 per share.

Financial and operating metrics:

Three months endedSeptember 30, Twelve months endedSeptember 30,
2026 2025 2026 2025
Cash flow: (dollars in millions)
Operating cash flow $         519 $         842 $       1,870 $       1,893
Free cash flow(1) $         276 $         604 $          980 $          996
_______________________
(1) For definitions of non-GAAP financial measures, see the note titled “Note on Non-GAAP Financial Measures” and related reconciliations beginning on page 14.
Three months ended September 30, 2026 Nine months ended September 30, 2026
Effective income tax rate on:
Income 24.9 % 21.8 %
Income attributable to DaVita Inc.(1) 28.7 % 26.5 %
Adjusted income attributable to DaVita Inc.(1) 26.6 % 25.8 %
_______________________
(1) For definitions of non-GAAP financial measures, see the note titled “Note on Non-GAAP Financial Measures” and related reconciliations beginning on page 14.

Center activity: As of September 30, 2026, we provided dialysis services to a total of approximately 298,100 patients at 3,269 outpatient dialysis centers, of which 2,671 centers were located in the United States and 598 centers were located in 14 countries outside of the United States.

Integrated kidney care (IKC): As of September 30, 2026, we had approximately 80,800 patients in risk-based integrated care arrangements representing approximately $6.4 billion in annualized medical spend. We also had an additional 3,100 patients in other integrated care arrangements; we do not include the medical spend for these patients in this annualized medical spend estimate. For an additional description of these metrics, see footnote 5 in the “Supplemental Financial Data” table below.

Outlook:

The following forward-looking measures and the underlying assumptions involve significant known and unknown risks and uncertainties, including those described below, and actual results may vary materially from these forward-looking measures. We do not provide guidance for operating income or diluted net income per share attributable to DaVita Inc. or operating cash flow on a basis consistent with United States generally accepted accounting principles (GAAP) nor a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts. These current non-GAAP financial measures do not include certain items, including goodwill impairment charges and foreign currency fluctuations, which may be significant. The guidance for our effective income tax rate on adjusted income attributable to DaVita Inc. also excludes the amount of third-party owners’ income and related taxes attributable to non-tax paying entities.

Current 2026 guidance Prior 2026 guidance
Low High Low High
(dollars in millions, except per share data)
Adjusted operating income $2,175 $2,250 $2,150 $2,250
Adjusted diluted net income per share attributable to DaVita Inc. $14.30 $15.20 $14.10 $15.20
Free cash flow $1,000 $1,250 $1,000 $1,250

The following table outlines normalized treatment days by quarter for 2025 and 2026. Normalized treatment days are adjusted for the mix of days of the week for each quarter and serve as a means to more readily compare calendar effects on each quarter’s treatment volume.

Normalized Treatment Days
2026 2025
Q1 76.5 76.9
Q2 78.0 78.0
Q3 79.2 78.8
Q4 78.8 79.5
Total 312.4 313.2

               Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

We will be holding a conference call to discuss our results for the third quarter ended September 30, 2026, on October 29, 2026, at 5:00 p.m. Eastern Time. To join the conference call, please dial (877) 918-6630 from the U.S. or (517) 308-9042 from outside the U.S., and provide the operator the password “Earnings.” This call is being webcast and can be accessed at the DaVita Investor Relations website investors.davita.com. A replay of the conference call will also be available at investors.davita.com.

Forward looking statements

DaVita Inc. and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this release, filings with the Securities and Exchange Commission (SEC), reports to stockholders and in meetings with investors and analysts. All statements in this release, during the related presentation or other meetings, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for “forward-looking statements” provided by the PSLRA. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, the impact of the cybersecurity incident experienced by the Company in 2025 (cyber incident), the impact of federal government policy changes or shutdowns on our business, including with respect to federal funding and reimbursement rates of Medicare, Medicare Advantage (MA), Medicaid and other government programs, availability or cost of supplies, including without limitation the impact of evolving trade policies and tariffs and any reduction in clinical and other supplies due to any disruptions experienced by third party vendors, including with respect to our ability to provide home dialysis services, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, including potential impacts to such mix as a result of U.S. administration policies, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our outlook, future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), MA plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, and expectations regarding our share repurchase program. All statements in this release, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words “expect,” “intend,” “will,” “could,” “plan,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita’s current expectations and are based solely on information available as of the date of this release. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:

  • external conditions, including those related to general economic, political and global health conditions, including without limitation, the impact of global events and political or governmental volatility, including in the Middle East and Ukraine; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the impact of infectious diseases or other adverse conditions on our financial condition, the chronic kidney disease population and our patient population; supply chain challenges and disruptions, including without limitation, with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain and cost of supplies as a result of global events, natural disasters or evolving trade policies, including tariffs; the impact on our patients and industry of continued increased competition from dialysis providers and others, including new or potential entrants in the dialysis and pre-dialysis marketplace; the impact of new or innovative technologies, drugs, or other treatments, including our ability to successfully implement new technologies, treatments or therapies in our business such as those related to middle molecule toxin clearance; elevated teammate turnover or labor costs; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities and execute on related strategic initiatives;

  • the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; our ability to negotiate and maintain contracts with these payors on competitive terms or at all; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of healthcare, immigration or other policies implemented by the U.S. administration, continuing legislative, regulatory or other efforts to restrict or prohibit the use and/or availability of charitable premium assistance, or as a result of payors implementing restrictive plan designs or resulting from negotiations with large commercial payors that we have in the past, and currently are, conducting on a concurrent basis;

  • risks arising from laws, regulations or requirements applicable to us or changes thereto, including, without limitation, the One Big Beautiful Bill Act and those related to trade policy, healthcare, charitable premium assistance, privacy, antitrust matters, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in interpretation or enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments;

  • our ability to successfully implement our strategies with respect to IKC and VBC initiatives that may be impacted by, among other things, changes to the Comprehensive Kidney Care Contracting model and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment;

  • a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure and adjustment methodologies;

  • our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products; and risks resulting from a closure, reduction, disruption or transition in the services or products provided to us by such suppliers, service providers and third party vendors, which may, among other things, increase our costs or expenses;

  • our ability to successfully and cost-effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely and our ability to successfully and cost-effectively adopt or adapt to new technologies, treatments or therapies, including technologies that utilize artificial intelligence;

  • legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business;

  • noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the cyber incident, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;

  • our ability to attract, retain and motivate teammates, including key leadership personnel, our ability to manage potential disruptions to our business and operations, including potential work stoppages, and our ability to manage operating cost increases or productivity decreases that may be related to political unrest, legislative or other changes, union organizing activities, or volatility and uncertainty in the current challenging and highly competitive labor market that has experienced an ongoing nationwide shortage of skilled clinical personnel, among other things;

  • changes in practice patterns, pricing, or reimbursement and payment policies or processes related to pharmaceuticals, medical equipment or supplies, including with respect to oral phosphate binders, among other things;

  • our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates;

  • our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to continue to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;

  • the variability of our cash flows, including, without limitation, any extended billing or collections cycles that may be due to, among other things, defects or operational issues in our billing systems such as those experienced during the cyber incident, or defects or operational issues in the billing systems or services of third parties on which we rely; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs;

  • the effects on us or others of natural or other disasters, public health crises or severe adverse weather events such as hurricanes, earthquakes, fires or flooding;

  • factors that may impact our ability to repurchase stock under our share repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock;

  • our goals and disclosures related to sustainability matters, including, among other things, evolving regulatory requirements affecting environmental, social and governance standards, measurements and reporting requirements; and

  • the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2026, and the risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.

The financial information presented in this release is unaudited and is subject to change as a result of subsequent events or adjustments, if any, arising prior to the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

DAVITA INC.CONSOLIDATED STATEMENTS OF INCOME(unaudited)(dollars and shares in thousands, except per share data)
Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
Dialysis patient service revenues $  3,408,266 $  3,298,090 $ 10,047,440 $  9,607,954
Other revenues 169,860 122,137 500,318 415,328
Total revenues 3,578,126 3,420,227 10,547,758 10,023,282
Operating expenses:
Patient care costs 2,451,047 2,332,759 7,185,305 6,833,959
General and administrative 408,697 414,373 1,254,069 1,201,268
Depreciation and amortization 165,188 177,490 510,825 528,645
Equity investment income, net (8,237) (10,162) (24,765) (23,135)
Goodwill and other asset impairment charges 62,176 — 62,176 —
Total operating expenses 3,078,871 2,914,460 8,987,610 8,540,737
Operating income 499,255 505,767 1,560,148 1,482,545
Debt expense (150,016) (150,557) (445,403) (431,674)
Debt extinguishment and modification costs — (5,150) (2,035) (5,150)
Other income (loss), net 9,468 (41,257) 22,241 (81,657)
Income before income taxes 358,707 308,803 1,134,951 964,064
Income tax expense 89,318 68,554 247,304 216,379
Net income 269,389 240,249 887,647 747,685
Less: Net income attributable to noncontrolling interests (46,458) (89,917) (201,789) (235,099)
Net income attributable to DaVita Inc. $    222,931 $    150,332 $    685,858 $    512,586
Earnings per share attributable to DaVita Inc.:
Basic net income $          3.49 $          2.09 $        10.50 $          6.77
Diluted net income $          3.40 $          2.04 $        10.27 $          6.62
Weighted average shares for earnings per share:
Basic shares 63,835 72,075 65,322 75,768
Diluted shares 65,504 73,769 66,811 77,442
DAVITA INC.CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(unaudited) (dollars in thousands)
Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
Net income $    269,389 $    240,249 $    887,647 $    747,685
Other comprehensive income (loss), net of tax:
Unrealized gains (losses) on interest rate cap agreements:
Unrealized gains (losses) 26,777 (4,418) 34,729 (19,358)
Reclassifications of net realized losses into net income 2,877 1,427 8,632 4,468
Unrealized (losses) gains on foreign currency translation (564) 24,669 49,961 209,526
Other comprehensive income 29,090 21,678 93,322 194,636
Total comprehensive income 298,479 261,927 980,969 942,321
Less: Comprehensive income attributable to noncontrolling interests (46,458) (89,917) (201,789) (235,099)
Comprehensive income attributable to DaVita Inc. $    252,021 $    172,010 $    779,180 $    707,222
DAVITA INC.CONSOLIDATED BALANCE SHEETS(unaudited)(dollars and shares in thousands, except per share data)
September 30, 2026 December 31, 2025
ASSETS
Cash and cash equivalents $        495,629 $        676,438
Restricted cash and equivalents 83,631 81,309
Short-term investments 70,673 24,303
Accounts receivable 2,509,014 2,414,690
Inventories 161,464 160,627
Contract assets and other receivables 565,459 494,414
Prepaid and other current assets 141,147 156,285
Income tax receivable 47,807 49,937
Total current assets 4,074,824 4,058,003
Property and equipment, net of accumulated depreciation of $6,985,414 and $6,602,134, respectively 2,731,171 2,812,966
Operating lease right-of-use assets 2,434,212 2,397,179
Intangible assets, net of accumulated amortization of $39,378 and $37,751, respectively 221,070 222,125
Equity method and other investments 404,305 157,249
Long-term investments 38,382 40,966
Other long-term assets 364,506 246,520
Goodwill 7,548,042 7,545,095
$     17,816,512 $     17,480,103
LIABILITIES AND EQUITY
Accounts payable $          662,199 $          696,148
Other liabilities 848,178 893,024
Accrued compensation and benefits 747,911 793,478
Current portion of operating lease liabilities 438,132 425,484
Current portion of long-term debt 112,491 109,201
Income tax payable 23,143 24,359
Due to related party 54,714 199,940
Total current liabilities 2,886,768 3,141,634
Long-term operating lease liabilities 2,185,179 2,175,658
Long-term debt 10,656,624 10,163,988
Other long-term liabilities 100,431 83,516
Deferred income taxes 861,693 756,869
Total liabilities 16,690,695 16,321,665
Commitments and contingencies
Noncontrolling interests subject to put provisions 1,484,283 1,532,166
Equity:
Preferred stock ($0.001 par value, 5,000 shares authorized; none issued) — —
Common stock ($0.001 par value, 450,000 shares authorized; 69,237 shares issued and 63,400 shares outstanding at September 30, 2026, and 68,549 shares issued and outstanding at December 31, 2025) 69 69
Additional paid-in capital 53,979 —
Accumulated earnings (deficit) 301,565 (328,428)
Treasury stock (5,837 and zero shares, respectively) (917,239) (199,940)
Accumulated other comprehensive loss (29,461) (122,783)
Total DaVita Inc. shareholders’ equity deficit (591,087) (651,082)
Noncontrolling interests not subject to put provisions 232,621 277,354
Total equity deficit (358,466) (373,728)
$     17,816,512 $     17,480,103
DAVITA INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(dollars in thousands)
Nine months ended September 30,
2026 2025
Cash flows from operating activities:
Net income $       887,647 $       747,685
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 510,825 528,645
Goodwill and other asset impairment charges 62,176 —
Loss on extinguishment of debt — 4,253
Stock-based compensation expense 83,378 101,559
Deferred income taxes 91,207 68,989
Equity investment loss, net 887 91,532
Other non-cash losses, net 14,668 11,522
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
Accounts receivable (67,585) (144,688)
Inventories 1,103 913
Other current assets (50,210) (153,428)
Other long-term assets (47,733) (21)
Accounts payable (47,803) 97,879
Accrued compensation and benefits (64,671) 19,279
Other current liabilities (50,713) 16,462
Income taxes 453 (30,635)
Other long-term liabilities 6,101 (14,172)
Net cash provided by operating activities 1,329,730 1,345,774
Cash flows from investing activities:
Additions of property and equipment (431,323) (430,434)
Acquisitions (41,693) (118,337)
Proceeds from asset and business sales 16,297 32,337
Purchase of debt investments held-to-maturity (66,788) (15,842)
Purchase of other debt and equity investments (29,832) (3,352)
Proceeds from debt investments held-to-maturity 17,020 38,051
Proceeds from sale of other debt and equity investments 4,382 6,706
Purchase of equity method investments (221,839) (2,466)
Distributions from equity method investments 329 1,514
Net cash used in investing activities (753,447) (491,823)
Cash flows from financing activities:
Borrowings 3,511,331 4,672,170
Payments on long-term debt (3,021,008) (3,880,721)
Deferred and debt related financing costs (10,602) (26,416)
Purchase of treasury stock from related party (419,318) (430,286)
Other purchases of treasury stock (450,862) (1,033,887)
Distributions to noncontrolling interests (243,786) (232,721)
Net proceeds from issuance of common stock under employee stock plans 14,509 17,583
Payment of tax withholdings on net share settlements of equity awards (68,968) (33,764)
Contributions from noncontrolling interests 4,636 3,999
Proceeds from sales of additional noncontrolling interests — 169
Purchases of noncontrolling interests (70,593) (16,385)
Net cash used in financing activities (754,661) (960,259)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (109) 21,897
Net decrease in cash, cash equivalents and restricted cash (178,487) (84,411)
Cash, cash equivalents and restricted cash at beginning of the year 757,747 879,825
Cash, cash equivalents and restricted cash at end of the period $       579,260 $       795,414
DAVITA INC.SUPPLEMENTAL FINANCIAL DATA(unaudited) (dollars in millions and shares in thousands, except per treatment and patient data)
Three months ended Nine months ended September 30, 2026
September 30, 2026 June 30, 2026
1. Consolidated business metrics:
Operating margin 14.0 % 16.3 % 14.8 %
Adjusted operating margin excluding certain items(1) 15.7 % 16.3 % 15.4 %
General and administrative expenses as a percent of consolidated revenues(2) 11.4 % 11.9 % 11.9 %
Effective income tax rate on income 24.9 % 21.1 % 21.8 %
Effective income tax rate on income attributable to DaVita Inc.(1) 28.7 % 25.6 % 26.5 %
Effective income tax rate on adjusted income attributable to DaVita Inc.(1) 26.6 % 25.6 % 25.8 %
2. Summary of financial results:
Revenues:
U.S. dialysis patient services and other $   3,050 $   3,012 $      9,004
Other—Ancillary services
Integrated kidney care 144 162 422
Other U.S. ancillary 10 9 29
International dialysis patient service and other 398 386 1,156
552 557 1,606
Eliminations (24) (14) (62)
Total consolidated revenues $   3,578 $   3,554 $    10,548
Operating income (loss):
U.S. dialysis $      544 $      538 $      1,588
Other—Ancillary services
Integrated kidney care 4 40 24
Other U.S. ancillary (6) (8) (20)
International (16) 25 40
(19) 57 44
Corporate administrative support expenses (26) (16) (72)
Total consolidated operating income $      499 $      579 $      1,560
DAVITA INC.SUPPLEMENTAL FINANCIAL DATA – continued(unaudited)(dollars in millions and shares in thousands, except per treatment and patient data)
Three months ended Nine months ended September 30, 2026
September 30, 2026 June 30, 2026
3. Summary of reportable segment financial results and metrics:
U.S. dialysis
Financial results
Revenue:
Dialysis patient service revenues $   3,044 $   3,005 $      8,984
Other revenues 7 7 20
Total operating revenues 3,050 3,012 9,004
Operating expenses:
Patient care costs 2,054 2,005 6,028
General and administrative 316 331 967
Depreciation and amortization 144 146 446
Equity investment income (8) (8) (25)
Total operating expenses 2,506 2,474 7,416
Segment operating income $     544 $     538 $      1,588
Metrics
Volume:
Treatments 7,329,644 7,226,600 21,585,769
Number of treatment days 79.0 78.0 233.7
Average treatments per day 92,780 92,649 92,365
Per day year-over-year change 1.2 % 0.6 % 0.5 %
Number of normalized treatment days(3) 79.2 78.0 233.7
Average treatments per normalized day 92,546 92,649 92,365
Per normalized day year-over-year change 0.7 % 0.6 % 0.5 %
Normalized year-over-year non-acquired treatment growth(4) 0.4 % 0.3 %
Operating net revenues:
Average patient service revenue per treatment $  415.25 $  415.87 $    416.22
Expenses:
Patient care costs per treatment $  280.22 $  277.40 $    279.24
General and administrative expenses per treatment $    43.14 $    45.79 $      44.79
Depreciation and amortization expense per treatment $    19.70 $    20.26 $      20.66
Accounts receivable:
Receivables $    1,684 $    1,719
DSO 51 52
4. IKC metrics:
Patients per integrated care arrangement type:
Risk-based(5) 80,800 64,900
Other(5) 3,100 5,700
Annualized aggregate risk based spend(5) $   6,400 $   5,800
DAVITA INC.SUPPLEMENTAL FINANCIAL DATA – continued(unaudited)(dollars in millions and shares in thousands, except per treatment and patient data)
Three months ended Nine months ended September 30, 2026
September 30, 2026 June 30, 2026
5. Cash flow:
Operating cash flow $      519 $       490 $        1,330
Operating cash flow, last twelve months $   1,870 $    2,193
Free cash flow(1) $      276 $       256 $           672
Free cash flow, last twelve months(1) $      980 $    1,308
Capital expenditures:
Maintenance $      112 $       123 $           309
Development $        47 $         47 $           122
Acquisition expenditures $          3 $           5 $             42
Proceeds from sale of self-developed properties $        10 $         — $             13
6. Debt and capital structure:
Total debt(6) $  10,832 $  10,848
Net debt, net of cash and cash equivalents(6) $  10,337 $  10,179
Leverage ratio(7) 3.38x 3.37x
Weighted average effective interest rate:
At end of the quarter 5.54 % 5.43 %
On the senior secured credit facilities at end of the quarter 6.02 % 5.76 %
Amount spent on share repurchases $        111 $       348 $           863
Number of shares repurchased 594 2,238 5,837
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
_______________________
(1) These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules. Adjusted operating income margin is adjusted operating income divided by consolidated revenues.
(2) General and administrative expenses include certain corporate support, long-term incentive compensation and advocacy costs.
(3) Normalized treatment days reflect treatment days adjusted to normalize for the mix of days of the week in a given quarter.
(4) Normalized non-acquired treatment growth reflects year-over-year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given quarter versus the prior year quarter.
(5) Integrated care metrics: The aggregate amount of medical spend associated with risk-based integrated care arrangements that we disclose includes both medical costs included in our reported expenses for certain risk-based arrangements (such as our SNPs), as well as the aggregate estimated benchmark amount above or below which we will incur profit or loss from value-based care (VBC) arrangements under which third-party medical costs are not included in our reported results. A number of our VBC contracts are subject to complex or novel patient attribution mechanics and benchmark adjustments, some of which are based on information not reported to us until periods after we report our quarterly results. As a result, our estimates of our patients under, and the dollar amount of, our value-based contracts remain subject to estimation uncertainty.
(6) The debt amounts presented as of September 30, 2026 and June 30, 2026 exclude approximately $63.1 and $66.5, respectively, of debt discount, premium and other deferred financing costs related to our senior secured credit facilities and senior notes in effect or outstanding at that time.
(7) This is a non-GAAP measure. See “Calculation of Leverage Ratio” in non-GAAP reconciliations.

**DAVITA INC.
****RECONCILIATIONS FOR NON-GAAP MEASURES
****(unaudited)
**(dollars in millions)

Calculation of the Leverage Ratio

Under our amended senior secured credit facilities (the Amended Credit Agreement) dated June 8, 2026, the leverage ratio is defined as (a) all funded debt, minus unrestricted cash and cash equivalents (including short-term investments) divided by (b) “Consolidated EBITDA.” The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A-2 and revolving line of credit under the Amended Credit Agreement by establishing the margin over the base interest rate (SOFR plus credit spread adjustment) that is applicable. The calculation below is based on the last 12 months of “Consolidated EBITDA” and “Consolidated net debt” at the end of each reported period, each as defined in the credit agreement that was in effect at the end of each such period (the Applicable Credit Agreement). The calculation of “Consolidated EBITDA” below sets forth, among other things, certain pro forma adjustments described in the Applicable Credit Agreement, including, pro forma adjustments for acquisitions or divestitures that occurred during the period and certain projected net cost savings, expense reductions and cost synergies. These pro forma adjustments are determined according to specified criteria set forth in the Applicable Credit Agreement, and as a result, the total adjustments calculated may not be comparable to the Company’s estimates for other purposes, including as operating performance measures. The Company’s management believes the presentation of “Consolidated EBITDA” is useful to investors to enhance their understanding of the Company’s leverage ratio under the Applicable Credit Agreement and should not be evaluated for any other purpose. The leverage ratio calculated by the Company is a non-GAAP measure and should not be considered a substitute for the ratio of total debt to operating income, determined in accordance with GAAP. The Company’s calculation of its leverage ratio might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures of other companies.

Twelve months ended
September 30, 2026 June 30, 2026
Net income from continuing operations attributable to DaVita Inc. $          895 $          822
Income taxes 324 303
Interest expense 543 540
Depreciation and amortization 698 710
Impairment charges 62 —
Net income attributable to noncontrolling interests 299 342
Stock-settled stock-based compensation 117 127
Debt extinguishment and modification costs 11 16
Expected cost savings and expense reductions 10 7
Other 84 149
Consolidated EBITDA $        3,042 $        3,018
September 30, 2026 June 30, 2026
Total debt, excluding debt discount and other deferred financing costs(1) $      10,832 $      10,848
Less: Cash and cash equivalents including short-term investments(2) (563) (685)
Consolidated net debt $      10,269 $      10,162
Last twelve months Consolidated EBITDA $        3,042 $        3,018
Leverage ratio 3.38x 3.37x
Maximum leverage ratio permitted under the Credit Agreement 5.00x 5.00x
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
______________________
(1) The debt amounts presented as of September 30, 2026 and June 30, 2026 exclude approximately $63.1 and $66.5, respectively, of debt discount, premium and other deferred financing costs related to our senior secured credit facilities and senior notes in effect or outstanding at that time.
(2) This excludes amounts not readily convertible to cash related to the Company’s non-qualified deferred compensation plans for all periods presented.

**DAVITA INC.
****RECONCILIATIONS FOR NON-GAAP MEASURES
**(unaudited)

Note on Non-GAAP Financial Measures

As used in this press release, the term “adjusted” refers to non-GAAP measures as follows, each as reconciled to its most comparable GAAP measure as presented in the non-GAAP reconciliations in the notes to this press release: (i) for income and expense measures, the term “adjusted” refers to operating performance measures that exclude certain items such as, but not limited to, cybersecurity costs, impairment charges, gains or losses on ownership changes, restructuring charges, accruals for legal matters, and debt extinguishment and modification costs; and (ii) the term “effective income tax rate on adjusted income attributable to DaVita Inc.” represents the Company’s effective tax rate excluding applicable non-GAAP items and the tax associated with them as well as noncontrolling owners’ income, which primarily relates to non-tax paying entities.

These non-GAAP or “adjusted” measures are presented because management believes these measures are useful adjuncts to GAAP results. However, these non-GAAP measures should not be considered alternatives to the corresponding measures determined under GAAP. 

Specifically, management uses adjusted operating income, adjusted net income attributable to DaVita Inc. and adjusted diluted net income per share attributable to DaVita Inc. to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe these non-GAAP measures also are useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. Furthermore, we believe these presentations enhance a user’s understanding of our normal consolidated results by excluding certain items which we do not believe are indicative of our ordinary results of operations. As a result, adjusting for these amounts allows for comparison to our normalized prior period results.

The effective income tax rate on adjusted income attributable to DaVita Inc. excludes noncontrolling owners’ income and certain non-deductible and other charges which we do not believe are indicative of our ordinary results. Accordingly, we believe these adjusted effective income tax rates are useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.

Finally, free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests, development capital expenditures, and maintenance capital expenditures; plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities and other measures under GAAP.

It is important to bear in mind that these non-GAAP “adjusted” measures are not measures of financial performance or liquidity under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.

The following tables provide reconciliations of the non-GAAP financial measures presented in this press release to their most comparable GAAP measures.

DAVITA INC.RECONCILIATIONS FOR NON-GAAP MEASURES – continued(unaudited)(dollars in millions, except per share data)
Adjusted net income and adjusted diluted net income per share attributable to DaVita Inc.:
Three months ended Nine months ended
September 30, 2026 June 30, 2026 September 30, 2026 September 30, 2025
Dollars Per share Dollars Per share Dollars Per share Dollars Per share
Consolidated:
Net income attributable to DaVita Inc. $  223 $  3.40 $  265 $  4.02 $  686 $ 10.27 $  513 $  6.62
Goodwill and other asset impairments(1) 62 0.95 — — 62 0.93 — —
Goodwill and other asset impairments attributable to noncontrolling interests(1) (34) (0.53) — — (34) (0.51) — —
Cybersecurity incident-related charges(2) — — — — — — 25 0.33
Other loss, net – Mozarc net loss(3) — — — — — — 26 0.33
Income tax impact related to prior legal matter(4) — — — — — — 19 0.24
Related income tax (1) (0.01) — — (1) (0.01) (6) (0.08)
Adjusted net income attributable to DaVita Inc. $  250 $  3.82 $  265 $  4.02 $  713 $ 10.67 $  576 $  7.44
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
Adjusted operating income:
Three months ended September 30, 2026
U.S.dialysis Ancillary services Corporateadministration
U.S. IKC U.S. Other International Total Consolidated
Operating income (loss) $   544 $        4 $      (6) $     (16) $   (19) $       (26) $     499
Goodwill and other asset impairments(1) — — — 62 62 — 62
Adjusted operating income (loss) $   544 $        4 $      (6) $      46 $     44 $       (26) $     561
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
Nine months ended September 30, 2026
U.S.dialysis Ancillary services Corporateadministration
U.S. IKC U.S. Other International Total Consolidated
Operating income (loss) $ 1,588 $      24 $     (20) $      40 $     44 $       (72) $   1,560
Goodwill and other asset impairments(1) — — — 62 62 — 62
Adjusted operating income (loss) $ 1,588 $      24 $     (20) $     102 $   106 $       (72) $   1,622
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
Nine months ended September 30, 2025
U.S. dialysis Ancillary services Corporate administration Consolidated
U.S. IKC U.S. Other International Total
Operating income (loss) $ 1,529 $     (24) $     (14) $      93 $     55 $     (101) $   1,483
Cybersecurity incident-related charges(2) 25 — — — — — 25
Adjusted operating income (loss) $ 1,554 $     (24) $     (14) $      93 $     55 $     (101) $   1,508
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
DAVITA INC.RECONCILIATIONS FOR NON-GAAP MEASURES – continued(unaudited)(dollars in millions, except per share data)
Effective income tax rates:
Three months ended Nine months endedSeptember 30, 2026
September 30, 2026 June 30, 2026
Effective income tax rates on income attributable to DaVita Inc.:
Income before income taxes $    359 $  435 $   1,135
Noncontrolling owners’ income primarily attributable to non-tax paying entities (46) (78) (202)
Income before income taxes attributable to DaVita Inc. $    313 $  357 $      933
Income tax expense $      89 $    92 $      247
Income tax benefit (expense) attributable to noncontrolling interests 1 (1) —
Income tax expense attributable to DaVita Inc. $      90 $    91 $      247
Effective income tax rate on income attributable to DaVita Inc. 28.7 % 25.6 % 26.5 %
Effective income tax rate on adjusted income attributable to DaVita Inc.:
Income before income taxes $    359 $  435 $   1,135
Goodwill and other asset impairments(1) 62 — 62
Noncontrolling owners’ income primarily attributable to non-tax paying entities (46) (78) (202)
Goodwill and other asset impairments attributable to noncontrolling interests(1) (34) — (34)
Adjusted income before income taxes attributable to DaVita Inc. $    341 $  357 $      961
Income tax expense $      89 $    92 $      247
Income tax benefit (expense) related to:
Goodwill and other asset impairments 1 — 1
Noncontrolling interests 1 (1) —
Income tax on adjusted income attributable to DaVita Inc. $      90 $    91 $      248
Effective income tax rate on adjusted income attributable to DaVita Inc. 26.6 % 25.6 % 25.8 %
Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.
DAVITA INC.RECONCILIATIONS FOR NON-GAAP MEASURES – continued(unaudited)(dollars in millions, except per share data)
Free cash flow:
Three months ended Nine months endedSeptember 30, 2026
September 30, 2026 June 30, 2026 September 30, 2025
Net cash provided by operating activities $       519 $       490 $       842 $       1,330
Adjustments to reconcile net cash provided by operating activities to free cash flow:
Distributions to noncontrolling interests (94) (64) (82) (244)
Contributions from noncontrolling interests — — 1 5
Maintenance capital expenditures(5) (112) (123) (119) (309)
Development capital expenditures(6) (47) (47) (47) (122)
Proceeds from sale of self-developed properties 10 — 8 13
Free cash flow $       276 $       256 $       604 $         672
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
Twelve months ended
September 30, 2026 June 30, 2026 September 30, 2025
Net cash provided by operating activities $     1,870 $     2,193 $     1,893
Adjustments to reconcile net cash provided by operating activities to free cash flow:
Distributions to noncontrolling interests (335) (323) (341)
Contributions from noncontrolling interests 8 9 8
Maintenance capital expenditures(5) (417) (424) (423)
Development capital expenditures(6) (160) (159) (178)
Proceeds from sale of self-developed properties 14 12 36
Free cash flow $       980 $     1,308 $       996
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
______________________
(1) Represents non-cash goodwill and other asset impairment charges related to our business in China, of which a portion was allocated to noncontrolling interests. These charges are excluded from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business, are inherently unpredictable and are non-cash amounts, the exclusion of which facilitates comparison of historical, current and forecasted financial results.
(2) Represents charges recognized to work to remediate a cybersecurity incident and restore systems following the occurrence of the incident in the second quarter of 2025. We have excluded these charges from our non-GAAP metrics as we do not believe they are indicative of our ordinary results of operations.
(3) Represents non-cash impairment and restructuring charges included in other losses related to our equity investment in Mozarc Medical Holding LLC. This loss does not represent a normal and recurring cost of operating our business or generating returns from investments and may obscure analysis of underlying trends and financial performance.
(4) Represents the write-down of a tax receivable related to a 2014 tax refund claim. The claim related to estimated tax expense associated with a legal matter previously presented as a non-GAAP adjustment. We have excluded this charge from our non-GAAP metrics because, among other things, we do not believe it is indicative of our ordinary results of operations because the charge is significant and may obscure analysis of underlying trends and financial performance of our current business.
(5) Maintenance capital expenditures represent capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures.
(6) Development capital expenditures principally represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions and relocations, and new or expanded contracted hospital operations.

Prompts

DaVita Inc. (ticker DVA), listed in United States.

Company History

Date Change Detail
Sep 6, 2016 Renamed DAVITA HEALTHCARE PARTNERS INC. → DAVITA INC.
Aug 2, 2012 Renamed DAVITA INC → DAVITA HEALTHCARE PARTNERS INC.
Oct 6, 2000 Renamed TOTAL RENAL CARE HOLDINGS INC → DAVITA INC

ETFs Holding DaVita Inc.

ETF Weight in ETF Shares Market value As of
OMAH 4.30% 274,392 $ 47.805M Nov 17, 2026
LSAT 3.52% 9,320 $ 2.238M Jul 31, 2026
STNC 3.36% 13,006 $ 3.123M Jul 31, 2026
SAGP 2.10% 7,223 $ 1.607M Jun 30, 2026
CPAI 2.00% 33,190 $ 7.384M Jun 30, 2026
WTV 1.64% 216,697 $ 48.211M Jun 30, 2026
AMOM 1.41% 1,399 $ 335.886K Jul 31, 2026
PY 0.85% 8,414 $ 1.872M Jun 30, 2026
BTAL 0.48% 6,072 $ 1.351M Jun 30, 2026
JMID 0.46% 456 $ 109.481K Jul 31, 2026
NQLT 0.42% 1,159 $ 203.996K Aug 31, 2026
ITAN 0.39% 2,809 $ 485.957K Nov 17, 2026
REMC 0.32% 49 $ 10.902K Jun 30, 2026
AFLG 0.31% 16,226 $ 2.827M Nov 16, 2026
AFMC 0.27% 4,092 $ 712.908K Nov 16, 2026
VFMF 0.25% 14,117 $ 2.485M Aug 31, 2026
VFMO 0.25% 27,566 $ 4.852M Aug 31, 2026
DFAS 0.20% 380,105 $ 66.165M Nov 12, 2026
VFVA 0.18% 9,818 $ 1.728M Aug 31, 2026
GVLU 0.16% 2,465 $ 429.452K Nov 17, 2026
IALT 0.08% 38,387 $ 6.688M Nov 16, 2026
VSLU 0.07% 1,738 $ 386.67K Jun 30, 2026
DFAC 0.05% 276,623 $ 48.152M Nov 12, 2026
SEIV 0.05% 3,538 $ 787.134K Jun 30, 2026
DCOR 0.05% 135,675 $ 23.617M Nov 12, 2026
DUHP 0.04% 46,923 $ 8.168M Nov 12, 2026
AVMC 0.04% 1,399 $ 243.734K Nov 16, 2026
GSPY 0.04% 1,686 $ 293.735K Nov 17, 2026
MSSM 0.03% 1,391 $ 244.83K Aug 31, 2026
CAPE 0.03% 364 $ 80.983K Jun 30, 2026
AAUS 0.03% 743 $ 130K Nov 18, 2026
DFSU 0.02% 2,596 $ 451.886K Nov 12, 2026
DFAU 0.02% 13,731 $ 2.39M Nov 12, 2026
DXUV 0.01% 3,853 $ 670.692K Nov 12, 2026
AVSU 0.01% 342 $ 59.583K Nov 16, 2026
AVLC 0.01% 496 $ 86.413K Nov 16, 2026
AVUQ 0.01% 193 $ 33.624K Nov 16, 2026
SFGV 0.01% 816 $ 140K Nov 18, 2026
HCMT 0.01% 225 $ 54.02K Jul 31, 2026
DFUS 0.01% 9,492 $ 1.652M Nov 12, 2026
MSLC 0.01% 1,396 $ 245.71K Aug 31, 2026
CSHP 0.00% 23 $ 4,007.06 Nov 16, 2026
DYNF 0.00% 24 $ 4,181.28 Nov 16, 2026
CORO 0.00% 21 $ 3,712.63 Nov 16, 2026
NTRL 0.00% 1,255 $ 0.00 Nov 16, 2026